文拉法辛治疗中枢介导性腹痛综合征的临床研究  

Clinical study of venlafaxine in the treatment of central mediated abdominal pain syndrome

作　　者：杜晨辉 刘露路[1] 王珏[1] 郑艳[1] 古赛[1] DU Chenhui;LIU Lulu;WANG Jue;ZHENG Yan;GU Sai(Department of Gastroenterology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院消化内科,重庆400016

出　　处：《现代医药卫生》2020年第8期1125-1127,共3页Journal of Modern Medicine & Health

摘　　要：目的分析不同疗程文拉法辛治疗中枢介导性腹痛综合征(CAPS)的临床应用效果。方法于2018年7月至2019年7月,将120例CAPS患者随机分为A、B、C、D组,分别予以文拉法辛缓释片(75毫克每次,每日1次)治疗1、3、6及9个月,记录治疗前、治疗结束时(治疗后)及停药6个月后患者汉密尔顿焦虑量表(HAMA)评分及视觉模拟量表(VAS)疼痛评分。结果治疗后,所有患者HAMA评分较治疗前均明显下降(P<0.05),A组与B组HAMA评分比较差异无统计学意义(P>0.05),C、D组评分高于A组(P<0.05),C、D组间比较差异无统计学意义(P>0.05)。治疗后,B、C、D组患者VAS疼痛评分较治疗前明显降低(P<0.05),且B、C、D组评分显著低于A组(P<0.05)。停药6个月后,A组HAMA评分较治疗后明显升高(P<0.05),B组HAMA及VAS疼痛评分均较治疗后明显升高(P<0.05),但C、D组较治疗后无明显变化(P>0.05)。结论采用文拉法辛6个月疗程治疗CAPS疗效显著,患者复发情况与9个月疗程接近,但经济性更高。Objective To investigate the clinical effects of different courses of venlafaxine treatment in patients with central-mediated abdominal pain syndrome(CAPS).Methods From July 2018 to July 2019,120 patients with CAPS were randomly divided into group A,B,C and D,and venlafaxine(75 mg,once a day)were given for 1,3,6 and 9 months respectively in each group.The Hamilton anxiety scale(HAMA)score and visual analogue scale(VAS)pain score were evaluated in all patients before,after and 6 months after the treatment.Results After treatment,HAMA scores of all patients decreased compared with those before treatment(P<0.05),and compared with group A,HAMA scores of group B were with no difference(P>0.05),but those of group C and D were significantly lower(P<0.05),while there was no significant difference between group C and D(P>0.05).After treatment,VAS pain scores of group B,C and D were significantly lower than those before treatment(P<0.05),and were also significantly lower than group A(P<0.05).Six months after drug withdrawal,HAMA scores in group A were significantly increased compared with the scores by the end of treatment(P<0.05),and both HAMA and VAS pain scores in group B were obviously increased(P<0.05),while neither HAMA nor VAS pain scores in group C and D were with significantly changes compared with those by the end of treatment(P>0.05).Conclusion The course of 6 months of venlafaxine treatment in patients with CAPS could be with fine economic efficiency,curative effect and low recurrence rate.

关 键 词：中枢介导性腹痛综合征 疼痛 焦虑障碍 文拉法辛 

分 类 号：R57[医药卫生—消化系统]